Stayble’s clinical phase 2b study has now also started in the Netherlands
Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.
The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include some 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain. The Company aims to recruit these patients during the coming 12 months. Patients will be treated with a single dose of STA363 and the longest follow-up is after 12 months.
CEO Andreas Gerward comments: The initiation of the first clinic in the Netherlands despite the challenges of the COVID-19 pandemic is a great achievement of my co-workers and collaboration partners. We are now looking forward to the first clinic being initiated in Spain and additional site initiations in Russia and the Netherlands.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se
Back